Benitec Biopharma Limited (NASDAQ:BNTC) Receives $26.00 Consensus PT from Analysts

Key Points

• Benitec Biopharma Limited (NASDAQ:BNTC) has received an average rating of "Buy" from eight analysts, with one assigning a "strong buy" rating and a consensus price target of $26.00.
• The company's recent earnings report showed that it beat expectations by posting an earnings per share (EPS) of ($0.24), surpassing the consensus estimate of ($0.36) by $0.12.
• Benitec Biopharma has seen significant institutional investment, with Geode Capital Management increasing its stake by 134.7% in the fourth quarter, indicating growing confidence in the company.

Shares of Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) have received a consensus rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $26.00.

A number of equities analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday, May 19th. TD Cowen initiated coverage on Benitec Biopharma in a research note on Monday, July 7th. They issued a "buy" rating for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $20.00 target price on shares of Benitec Biopharma in a research note on Thursday, May 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Benitec Biopharma by 1,104.3% in the 1st quarter. GAMMA Investing LLC now owns 77,605 shares of the biotechnology company's stock valued at $1,010,000 after acquiring an additional 71,161 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after acquiring an additional 20,597 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after acquiring an additional 13,425 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Benitec Biopharma by 134.7% in the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock valued at $2,490,000 after purchasing an additional 113,109 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in shares of Benitec Biopharma by 198.5% in the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after purchasing an additional 1,739,904 shares during the period. Hedge funds and other institutional investors own 52.19% of the company's stock.

Benitec Biopharma Price Performance

Shares of Benitec Biopharma stock traded down $0.07 during trading on Tuesday, hitting $12.60. 8,269 shares of the stock traded hands, compared to its average volume of 70,436. The stock has a market cap of $330.62 million, a price-to-earnings ratio of -8.40 and a beta of 0.40. Benitec Biopharma has a 52 week low of $8.06 and a 52 week high of $17.15. The firm's fifty day moving average is $12.99 and its 200-day moving average is $13.05. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.12. Research analysts expect that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.